Last mentioned: Mar 26, 2026
Paysign 2026 Outlook
Paysign projects 30-35% revenue growth for the coming fiscal year.
Recombinant Albumin Launch
Dyadic and ProLiant initiate commercial launch of recombinant albumin.
Dyadic Year-End Cash
Dyadic ends fiscal year with $8.6 million in cash and liquid assets.
Precigen Commercial Launch
Initial commercial shipments of Papzimius for adult RRP begin.
The Q4 2025 earnings cycle marks a critical transition for mid-cap biotech and health-IT firms as they shift from R&D-heavy profiles to commercial-stage entities. Key players like Dyadic and Precigen are reporting initial product revenues and expanded distribution networks, while service providers like Paysign see massive growth in patient affordability programs.
This page surfaces every story mentioning Paysign across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Paysign was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |